Cytogen to ship ProstaScint to first 65 certified sites in early 1997 following Oct. 28 approval.
This article was originally published in The Gray Sheet
CYTOGEN's PROSTASCINT INITIAL AVAILABILITY WILL BE LIMITED TO 65 SITES certified by the American College of Nuclear Physicians, Cytogen President and CEO Thomas McKearn, MD, PhD, said during an Oct. 29 analyst teleconference following approval of the prostate cancer diagnostic imaging agent on Oct. 28. "Using our `Partners in Excellence' program, which involves training people and certifying them in the proper interpretation of the test results...we will be in the marketplace with about 65 of these sites by the time we introduce the product," McKearn said. Cytogen plans to launch the product in early 1997.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.